The health care debate thread.

[Diehard Ute]

I wonder if this drug falls into the niche of being generic, but there not being enough demand to generate competition, sort of a less provocative version of the Martin Shlecki / Epi-pen controversy last year?

I have a teammate with severe RA. I'll ask them.

The potential of personalized medicine is immense, but it runs headlong into the historic way we've created medicines: FDA / Patents / generics / market size constraints.

You actually can't make a generic. Remicade is made from biological cells. So you can make a "bio-similar" medication but not an actual generic copy.


Sent from my iPhone using Tapatalk